Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. TLT
10. AMZN

Go back to Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Relmada Therapeutics (RLMD) Misses Q2 EPS by 9c

August 10, 2021 4:39 PM EDT

Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($1.56), $0.09 worse than the analyst estimate of ($1.47).

As of June 30, 2021, the Company had cash, cash equivalents, and short term investments of $109.1 million, compared to cash, cash equivalents, and short term investments of approximately $117.1 million at December 31,... More